Repligen Corp
RGEN120.230USD
+1.540+1.30%
Close 09/10, 16:00（ET）Quotes delayed by 15 min
6.76BMarket Cap
LossP/E TTM
More Details of Repligen Corp Company
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Company Info
Ticker SymbolRGEN
Company nameRepligen Corp
IPO dateApr 29, 1986
CEOMr. Olivier Loeillot
Number of employees1778
Security typeOrdinary Share
Fiscal year-endApr 29
AddressBuilding 1, Suite 100
CityWALTHAM
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02453
Phone17814499560
Websitehttps://www.repligen.com/
Ticker SymbolRGEN
IPO dateApr 29, 1986
CEOMr. Olivier Loeillot
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
91.29K
+1.08%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
32.55K
+3.08%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
14.31K
-14.90%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
12.56K
+147.18%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
4.94K
+24.53%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
3.32K
+41.49%
Dr. Konstantin Konstantinov, Ph.D.
Dr. Konstantin Konstantinov, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jason K. Garland
Mr. Jason K. Garland
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Tony John Hunt
Mr. Tony John Hunt
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Martin D. Madaus, Ph.D.
Dr. Martin D. Madaus, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
91.29K
+1.08%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
32.55K
+3.08%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
14.31K
-14.90%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
12.56K
+147.18%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
4.94K
+24.53%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
3.32K
+41.49%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
North America
84.59M
50.00%
Europe
59.21M
35.00%
APAC/Other
25.38M
15.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
8.37%
T. Rowe Price Associates, Inc.
6.10%
Roy T. Eddleman UEO
5.89%
Point72 Asset Management, L.P.
3.40%
Other
67.25%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
8.37%
T. Rowe Price Associates, Inc.
6.10%
Roy T. Eddleman UEO
5.89%
Point72 Asset Management, L.P.
3.40%
Other
67.25%
Shareholder Types
Shareholders
Proportion
Investment Advisor
59.57%
Investment Advisor/Hedge Fund
25.36%
Hedge Fund
13.00%
Individual Investor
6.39%
Research Firm
2.39%
Pension Fund
2.37%
Bank and Trust
0.68%
Sovereign Wealth Fund
0.59%
Family Office
0.50%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1028
61.98M
110.32%
-3.21M
2025Q1
1054
62.91M
111.98%
-2.72M
2024Q4
1054
61.13M
109.11%
-3.76M
2024Q3
1046
60.75M
108.48%
-6.10M
2024Q2
1039
61.28M
109.67%
-2.73M
2024Q1
1036
60.56M
108.45%
-5.41M
2023Q4
1062
62.13M
111.29%
-2.30M
2023Q3
1063
61.47M
110.27%
+2.91M
2023Q2
1050
59.01M
105.99%
+1.34M
2023Q1
1061
58.23M
104.67%
+1.01M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
5.07M
9.02%
-21.20K
-0.42%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.89M
8.7%
+13.96K
+0.29%
Mar 31, 2025
T. Rowe Price Associates, Inc.
7.52M
13.38%
+427.74K
+6.03%
Mar 31, 2025
Roy T. Eddleman UEO
3.31M
5.89%
-67.50K
-2.00%
Dec 31, 2024
Point72 Asset Management, L.P.
1.12M
1.99%
+197.82K
+21.53%
Mar 31, 2025
State Street Global Advisors (US)
1.69M
3.01%
-2.27K
-0.13%
Mar 31, 2025
Champlain Investment Partners, LLC
1.46M
2.61%
-79.53K
-5.15%
Mar 31, 2025
Sands Capital Management, LLC
1.29M
2.3%
-70.06K
-5.14%
Mar 31, 2025
Invesco Advisers, Inc.
1.60M
2.84%
+768.85K
+93.02%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Alger Mid Cap 40 ETF
4.16%
First Trust NYSE Arca Biotechnology Index Fund
3.18%
Invesco Biotechnology & Genome ETF
2.7%
BNY Mellon Innovators ETF
2.6%
iShares Health Innovation Active ETF
1.64%
VanEck Biotech ETF
1.39%
Franklin Genomic Advancements ETF
1.24%
Congress SMid Growth ETF
1.24%
WisdomTree BioRevolution Fund
1%
Pacer US Export Leaders ETF
0.93%
View more
Alger Mid Cap 40 ETF
Proportion4.16%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.18%
Invesco Biotechnology & Genome ETF
Proportion2.7%
BNY Mellon Innovators ETF
Proportion2.6%
iShares Health Innovation Active ETF
Proportion1.64%
VanEck Biotech ETF
Proportion1.39%
Franklin Genomic Advancements ETF
Proportion1.24%
Congress SMid Growth ETF
Proportion1.24%
WisdomTree BioRevolution Fund
Proportion1%
Pacer US Export Leaders ETF
Proportion0.93%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
